College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Pharmacoeconomics. 2010;28(7):539-53. doi: 10.2165/11536170-000000000-00000.
This study assessed the state of health economic evaluation (including pharmacoeconomic) research in Nigeria. A literature search was conducted to identify health economic articles pertaining to Nigeria. Two reviewers independently scored each article in the final sample using a data collection form designed for the study. A total of 44 studies investigating a wide variety of diseases were included in the review. These articles were published in 34 different journals, mostly based outside of Nigeria, between 1988 and 2009. On average, each article was written by four authors. Most first authors had medical/clinical affiliations and resided in Nigeria at the time of publication of the study. Based on a 1 to 10 scale, with 10 indicating the highest quality, the mean quality score for all studies was 7.29 (SD 1.21) and 59% of the articles were of fair quality (score 5-7); 5% were of even lower quality. The quality of articles was statistically significantly (p < or = 0.05) related to the country of residence of the primary author (non-Nigeria = higher), country of the journal (non-Nigeria = higher), primary objective of the study (economic analysis = higher) and type of economic analysis conducted (economic evaluations higher than cost studies). The conduct of health economic (including pharmacoeconomic) research in Nigeria was limited and about two-thirds of published articles were of sub-optimal quality. More and better quality health economic research in Nigeria is warranted.
这项研究评估了尼日利亚卫生经济评估（包括药物经济学）研究的现状。进行了文献检索，以确定与尼日利亚相关的卫生经济文章。两名评审员使用为研究设计的数据收集表，独立对最终样本中的每篇文章进行评分。共有 44 项研究调查了各种疾病，这些文章发表在 34 种不同的期刊上，其中大部分期刊都不在尼日利亚，发表时间在 1988 年至 2009 年之间。平均而言，每篇文章有四位作者撰写。大多数第一作者都有医学/临床背景，并且在研究发表时居住在尼日利亚。根据 1 到 10 的评分标准，其中 10 表示最高质量，所有研究的平均质量评分为 7.29（标准差 1.21），59%的文章质量为中等（评分 5-7）；5%的文章质量甚至更低。文章的质量与主要作者的居住国（非尼日利亚=更高）、期刊的国家（非尼日利亚=更高）、研究的主要目标（经济分析=更高）和进行的经济分析类型（经济评估高于成本研究）显著相关（p≤0.05）。尼日利亚的卫生经济（包括药物经济学）研究有限，约三分之二的已发表文章质量欠佳。需要在尼日利亚进行更多和更好质量的卫生经济研究。
